

Liste der bewilligten Forschungsprojekte 2024 *Liste des projets de recherche acceptés en 2024*

Basic research

Arnold Isabelle | Exploring eosinophil function in progressive colorectal cancer stages and metastasis in the era of transcriptomics

Institute of Experimental Immunology, Universität Zürich (UZH), Zurich
CHF 369 644 | 36 months | KFS-6248-08-2024

Basler Konrad | Investigating the similarities and differences between left- and right-sided colon cancer: a metastasis focus

Institut für Molekulare Biologie, Universität Zürich (UZH), Zürich
CHF 207 500 | 18 months | KFS-6031-02-2024

Becher Burkhard | Targeting IL-23R on tumour-infiltrating Tregs for cancer immunotherapy

Institute of Experimental Immunology, Universität Zürich (UZH), Zürich
CHF 351 578 | 36 months | KFS-6022-02-2024

Beerenwinkel Niko | Profiling tumour evolution in ovarian cancer for precision oncology

Department of Biosystems Science and Engineering, Eidgenössische Technische Hochschule (ETH), Basel
CHF 373 051 | 36 months | KFS-6058-02-2024

Cejka Petr | Towards mechanistic understanding of secondary DNA structure processing underlying synthetic lethality in cancer therapy

USI, Istituto di Ricerca in Biomedicina (IRB), Bellinzona
CHF 369 060 | 36 months | KFS-6136-08-2024

Coukos George | Laboratory evolution of cell states for next generation T cell cancer immunotherapy

Department of Oncology, Centre hospitalier universitaire vaudois (CHUV), Lausanne
CHF 358 143 | 48 months | KFS-6060-02-2024

De Palma Michele | Rewiring lung cancer immunity with engineered dendritic cell progenitors
Swiss Institute for Experimental Cancer Research (ISREC), Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne
CHF 366 980 | 48 months | KFS-6045-02-2024

Fernandez Gonzalez Santiago | Influence of the lymphatic versus hematogenous dissemination of B cell lymphoma in the immune response
Infection and Immunity, Istituto di Ricerca in Biomedicina (IRB), Bellinzona
CHF 346 738 | 48 months | KFS-6092-02-2024

Gönczy Pierre | Uncovering centriole number control mechanisms in health and cancer
SV ISREC UPGON, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne 15
CHF 373 980 | 36 months | KFS-6018-02-2024

Hess Christoph | Defining the metabolic and non-metabolic roles of QPRT in EBV-driven B cell lymphoma
Departement Biomedizin (DBM), Universität Basel, Basel
CHF 374 535 | 36 months | KFS-6254-08-2024

Janscak Pavel | Revisiting the molecular mechanisms underlying DNA replication stress induced by the chemotherapeutic agents cisplatin and mitomycin C
Institut für Molekulare Krebsforschung (Doppelinstitut MeF/MNF) (IMCR), Universität Zürich (UZH), Zürich
CHF 249 852 | 24 months | KFS-6145-08-2024

Jourdain Alexis | Blocking nucleoside catabolism to starve tumours
Immunobiology (formerly Biochemistry), Université de Lausanne (UNIL), Epalinges
CHF 375 000 | 48 months | KFS-6029-02-2024

Marti Thomas | Repurposing of the anti-epileptic drug stiripentol for cancer therapy
Clinic of Thoracic Surgery, Inselspital Bern, Bern
CHF 371 250 | 36 months | KFS-6228-08-2024

Nombela Arrieta Cesar | Inflammation-driven remodeling of the bone marrow microenvironment in the pathogenesis of acute myeloid leukemia
Medical Oncology and Hematology, Universität Zürich (UZH), Zürich
CHF 374 656 | 48 months | KFS-6235-08-2024

Pruschy Martin | Impact of draining lymph node irradiation during radioimmunotherapy on tumour dissemination
Departement für Radio-Onkologie, Universitätsspital Zürich (USZ), Zürich
CHF 249 240 | 24 months | KFS-6223-08-2024

Riek Roland | A new strategy to treat MAPK inhibitor resistant melanomas using the amyloid fold
Departement Chemie und Angewandte Biowissenschaften (D-CHAB), Eidgenössische Technische Hochschule (ETH), Zürich
CHF 374 640 | 48 months | KFS-6068-02-2024

Stucki Manuel | Targeting mitotic DNA damage tolerance pathways as a strategy to treat BRCA1/2-deficient cancers
Department of Gynecology, Universitätsspital Zürich (USZ), Schlieren
CHF 299 439 | 36 months | KFS-6185-08-2024

Tamburini Jerome | Targeting iron metabolism to eliminate quiescent leukemic stem cells in acute myeloid leukaemia

Medical specialities, Université de Genève (UNIGE), Genève

CHF 369 619 | 36 months | KFS-6032-02-2024

Theurillat Jean-Philippe | Understanding and co-targeting FOXA1 & FOXA2 in prostate cancer progression

Institute of Oncology Research, Institute of Oncology Research (IOR), Bellinzona

CHF 368 532 | 36 months | KFS-6178-08-2024

Weller Michael | Vortioxetine against glioblastoma: drug repurposing meets cancer neuroscience

Department of Neurology and Laboratory of Molecular Neurooncology, Universitätsspital Zürich (USZ), Zurich

CHF 341 833 | 36 months | KFS-6084-02-2024

Zavolan Mihaela | Discovery and functional characterization of HCC-associated small peptides

Biozentrum, Universität Basel, Basel

CHF 371 379 | 36 months | KFS-6181-08-2024

Clinical Research – laboratory-oriented

Bertholet Jenny | Simultaneous optimization of radiation therapy in space and time: a new horizon for Temporally Feathered Radiation Therapy (TFRT)

Division of Medical Radiation Physics and Department of Radiation Oncology, Inselspital Bern, Bern

CHF 249 826 | 48 months | KFS-6163-08-2024

Latorre Daniela | The immune cells in checkpoint inhibitor-associated neuromuscular inflammation - dissecting potential therapeutic targets

D-Biol, Eidgenössische Technische Hochschule (ETH), Zurich

CHF 364 265 | 36 months | KFS-6205-08-2024

Moeckli Raphaël | FLIRT: FLASH irradiation treatment planning to facilitate and optimize glioblastoma treatments with very-high energy electron FLASH radiation therapy

Institut de Radiophysique, Centre hospitalier universitaire vaudois (CHUV), Lausanne

CHF 251 143 | 48 months | KFS-6020-02-2024

Perentes Jean Yannis | Understanding how the immunogenic cell death caused by hyperthermic intrathoracic cisplatin chemotherapy improves the control of malignant pleural disease alone or in combination with immunotherapy

Service de chirurgie thoracique, Centre hospitalier universitaire vaudois (CHUV), Lausanne

CHF 322 614 | 36 months | KFS-6215-08-2024

Silina Karina | Identification of survival-relevant immunological features in lung cancer

Department of Chemistry and Applied Biosciences, Eidgenössische Technische Hochschule (ETH), Zurich

CHF 312 500 | 30 months | KFS-6108-02-2024

Vassella Erik | Overcoming resistance to temozolomide and immunotherapy by targeting the nonsense-mediated mRNA decay pathway in glioblastoma tumours

Institute of Tissue Medicine and Pathology, Universität Bern (UniBE), Bern
CHF 349 842 | 48 months | KFS-6061-02-2024

Wirsching Hans-Georg | Radiation-associated meningioma molecular profiling to inform targeted therapies (RAMPIT)

Neurology, UniversitätsSpital Zürich (USZ), Zürich
CHF 371 188 | 48 months | KFS-6103-02-2024

Zippelius Alfred | Unravelling the relevance of intratumoral NK cell subtypes in lung cancer using multimodal single cell and spatial analysis

Medical Oncology, Laboratory Cancer Immunology, Department Biomedicine, Universitätsspital Basel (USB), Basel
CHF 304 265 | 24 months | KFS-6233-08-2024

Clinical Research – patient-oriented

Bösch Maximilian | Fibre-Boost: A multicentre, 2:1 randomized, controlled trial to study the effects of a high-fibre dietary intervention on ctDNA clearance and the microbial and immunological landscape in immune checkpoint blockade-treated advanced non-small cell lung cancer

Lung Center, Kantonsspital St. Gallen (KSSG), St.Gallen
CHF 374 950 | 36 months | KFS-6039-02-2024

Gotta Verena | Prospective pharmacologic characterization of a novel cytomegalovirus-infection prophylaxis (Letermovir) in paediatric hematopoietic cell transplantation patients using endogenous Coproporphyrin (LetPeCo)

Pädiatrische Klinische Pharmazie / Pediatric Pharmacology and Pharmacometrics, Universitäts-Kinderspital beider Basel (UKBB), Basel
CHF 167 580 | 42 months | KFS-6041-02-2024

Heinzelmann-Schwarz Viola | Continuation of MATAO-Trial “Maintenance therapy with aromatase inhibitor in epithelial ovarian cancer: a phase III randomized double-blind placebo-controlled trial”

Gynecological Oncology, Universitätsspital Basel (USB), Basel
CHF 357 846 | 36 months | KFS-6066-02-2024

Petignat Patrick | Validation of AI-assisted digital telecytology for the triage of HPV-positive women in a same-day ‘Test-triage-treat’ strategy in Cameroon

Unité d'oncogynécologie chirurgicale, Université de Genève (UNIGE), Genève
CHF 375 000 | 36 months | KFS-6044-02-2024

Toso Christian | Assessing the impact of surgery on the immunity against hepatocellular carcinoma and on the use of immune check point inhibitors

Université de Genève (UNIGE)
CHF 370 517 | 36 months | KFS-6186-08-2024

Weber Walter Paul | Tailored axillary surgery de-escalation in patients with clinically node-positive breast cancer

Surgery, Universitätsspital Basel (USB), Basel
CHF 371 190 | 36 months | KFS-6184-08-2024

Wenning Anna Silvia | TOPANC Trial: Survival after TOtal versus partial PANCreaticoduodenectomy for adenocarcinoma of the pancreatic head, distal cholangiocarcinoma and ampullary cancer: a prospective multi-centric randomized controlled trial

Department for Visceral Surgery and Medicine, Inselspital Bern, Bern
CHF 365 960 | 48 months | KFS-6043-02-2024

Zilli Thomas | STAMPEDE2: A randomised controlled platform trial testing treatments in metastatic hormone sensitive prostate cancer - SABR Comparison S

Radiation Oncology, Ente Ospedaliero Cantonale (EOC), Bellinzona
CHF 373 151 | 48 months | KFS-6158-08-2024

Epidemiological research

Katapodi Maria | CASCADE III: Designing risk-stratified models of survivorship care for HBOC and Lynch syndrome families

Clinical Research, Faculty of Medicine, Universität Basel, Basel
CHF 374 999 | 36 months | KFS-6088-02-2024

Rothermundt Christian | Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS)

Bereich Onkologie / Hämatologie, Kantonsspital St. Gallen (KSSG), St. Gallen
CHF 217 760 | 48 months | KFS-6034-02-2024

Schaffar Robin | Cancer risk and prognosis among Individuals with Incarceration Experience: A Comprehensive Study in Geneva, Switzerland

Registre Genevois des Tumeurs, Université de Genève (UNIGE), Genève
CHF 157 338 | 24 months | KFS-6201-08-2024

Schindera Christina | Prospective multicentre cohort study of cardiac dysfunction in childhood cancer survivors: extension of the CardioOnco Study

University Children's Hospital Basel, Universität Basel, Basel
CHF 374 409 | 36 months | KFS-6096-02-2024

Spycher Ben D. | Residential exposure to agricultural pesticides and the risk of childhood cancer

Institute of Social and Preventive Medicine, Universität Bern (UniBE), Bern
CHF 351 418 | 36 months | KFS-6225-08-2024

Health services research

Cathomas Richard | Oncological and functional follow-up after cystectomy and trimodal therapy (INFORMATORY)

Onkologie, Kantonsspital Graubünden (KSGR), Chur

CHF 313 777 | 48 months | KFS-6065-02-2024

Cobos Munoz Daniel | Enhancing palliative care in Lao PDR: addressing the unmet needs

Epidemiology and Public Health, Schweizerisches Tropen- und Public Health-Institut (Swiss TPH), Allschwil

CHF 276 606 | 36 months | KFS-6082-02-2024

Maessen Maud | The impact of care goals on costs of inpatient palliative care patients with cancer. Have we been comparing apples and oranges?

University centre of palliative care, Inselspital Bern, Bern

CHF 105 680 | 18 months | KFS-6062-02-2024

Schwenkglens Matthias | Pre-planned health economic analysis of SAKK 96/12: prevention of symptomatic skeletal events with denosumab administered every 4 weeks versus every 12 weeks – a non-inferiority phase III trial

Department of Public Health, Universität Basel, Basel

CHF 88 497 | 30 months | KFS-6193-08-2024

Tolotti Angela | Advanced Practice Nursing in an oncology palliative care setting and its effects on patient autonomy, engagement and interprofessional collaboration: an implementation mixed-method pre-post study

Nursing research and development unit, Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona

CHF 193 929 | 36 months | KFS-6023-02-2024

Psychosocial research

Sommer Grit | Exploring trends of health-related quality of life after childhood cancer and its drivers/determinants: A longitudinal study

Institute of Social and Preventive Medicine, Universität Bern (UniBE), Bern

CHF 366 775 | 36 months | KFS-6105-02-2024

Wünsch Alexander | Empowering medical literacy in patients by pathology, oncology, onconursing and oncopsychology with explanation and rationalisation (EMPPO3WER): feasibility study with mixed methods

Universitätsklinik für Medizinische Onkologie, Inselspital Bern, Bern

CHF 286 408 | 36 months | KFS-6151-08-2024

Fellowships

Guedj Danaé | Exploring and exploiting HPV-specific CD4 T cells for head and neck squamous cell cancer immunotherapy

Département de pathologie et d'immunologie, Université de Genève (UNIGE), Genève 4
CHF 138 712 | 24 months | MD-PhD-6133-02-2024

Peres Tobias | Real world data of Nivolumab/Relatlimab in patients with melanoma brain metastasis

Medical Oncology / Hematology, Kantonsspital St. Gallen (KSSG), St. Gallen
CHF 62 600 | 12 months | KFS-6101-02-2024 BIL

Thavayogarajah Tharshika | Identifying the role of WRN in clonal haematopoiesis

Department of Hematology and Oncology, Universitätsspital Zürich (USZ), Zürich
CHF 126 000 | 24 months | KFS-6067-02-2024 BIL

Trepl Julia | Deciphering lung cancer metastasis through clonal and microenvironmental analysis

Medizinische Onkologie und Hämatologie, Universitätsspital Zürich (USZ), Zürich
CHF 125 600 | 24 months | KFS-6220-08-2024 BIL